Trials / Unknown
UnknownNCT06256549
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
A Multicenter, Randomized, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 272 (actual)
- Sponsor
- Gan and Lee Pharmaceuticals, USA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GZR18 | Titrated to low dose or middle or high dose |
| DRUG | Semaglutide | Titrated to 1.0 mg once a week |
Timeline
- Start date
- 2023-08-09
- Primary completion
- 2024-07-20
- Completion
- 2024-07-20
- First posted
- 2024-02-13
- Last updated
- 2024-02-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06256549. Inclusion in this directory is not an endorsement.